# To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

> **NCT02974426** · PHASE3 · TERMINATED · sponsor: **Shanghai Chest Hospital** · enrollment: 132 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage IIIA
- Radiotherapy

## Interventions

- **RADIATION:** PORT-first
- **RADIATION:** PORT-last
- **DRUG:** Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

## Key facts

- **NCT ID:** NCT02974426
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11
- **Primary completion:** 2024-02
- **Final completion:** 2024-02
- **Target enrollment:** 132 (ACTUAL)
- **Why stopped:** Enrollment was delayed and the number of eligible patients significantly declined with the use of neoadjuvant or adjuvant ICIs and TKIs therapies. Thus, this trial was closed due to insufficient accrual.
- **Last updated:** 2024-06-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974426, "To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02974426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*